Q4 2024 Management View CEO Raymond Tesi highlighted the transformative potential of 2024 for INmune Bio, emphasizing upcoming milestones. He noted the Phase 2 trial of XPro for Alzheimer's disease, ...
Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in people with this rare and serious genetic disease that prevents the body from ...
Dilgen, a 22-year-old Tottenville resident, has been battling epidermolysis bullosa (EB), a rare, life-threatening genetic ...
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation. Read why KRYS ...
The therapy targets the underlying genetic cause of DEB and has shown promising results in clinical studies, with experts expressing enthusiasm for this landmark treatment option. If approved ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa ...
for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. The CHMP’s ...
Hosted on MSN25d
LGND: First Steps into Cell & Gene Therapyand Regenerative Medicine Advanced Therapy designations for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) by the FDA. Another treatment for DEB was approved in 2023 branded ...
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) ...
LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback